Dupilumab reduces exacerbation in both early and late onset asthma: CHEST

Published On 2019-11-10 13:50 GMT | Update On 2019-11-10 13:50 GMT

USA: Dupilumab, a fully human monoclonal antibody, is beneficial for patients with early-or late-onset asthma, finds a recent study published in the CHEST journal. The study was also presented at the annual meeting of the American College of Chest Physicians.

According to the study, the administration of dupilumab in patients with uncontrolled, moderate to severe EOA or LOA reduced severe exacerbations and improved lung function. Grater reductions in exacerbations were found in patients with LOA. Also, dupilumab was generally well tolerated.

Dupilumab (Dupixent) is a monoclonal antibody used for the treatment of allergic diseases. It exhibits its action by blocking the shared receptor component for interleukin (IL)-4 and IL-13 -- key drivers of inflammation.

Nicola Hanania, of Baylor College of Medicine in Houston, and colleagues conducted a subanalysis of the LIBERTY ASTHMA QUEST study. Previous data from the study had shown dupilumab reduced exacerbations and improved lung function in patients with uncontrolled, moderate to severe asthma compared to patients who received placebo.

In the present study, the researchers evaluated the efficacy of dupilumab, given at 200 mg or 300 mg every 2 weeks, in patients with early-onset asthma (at 40 years of age or younger) and late-onset asthma (at 41 years or older). The analysis included 919 patients with early-onset asthma who received dupilumab and 450 early-onset patients who received placebo. There were 345 patients with late-onset asthma who received dupilumab and 188 late-onset patients who received placebo.

Read Also: Dupilumab reduces exacerbation rates in asthma patients

Key findings of the study include:

Dupilumab significantly reduced the adjusted annualized severe exacerbation rates during the 52-week treatment period.

Significant reductions occurred in both early- and late-onset patients, though reductions were greater in the late-onset group.

In early-onset patients, dupilumab reduced severe exacerbations by 38% when given at 200 mg and by 37% when given at 300 mg (P less than .001 vs. placebo). In late-onset patients, dupilumab reduced exacerbations by 64% and 69%, respectively (P less than .001 vs. placebo).

reductions in exacerbation rates were greatest in patients with elevated blood eosinophils (150 cells/mcL or greater) or fractional exhaled nitric oxide (FeNO; 25 ppb or greater).

In patients with early-onset asthma and elevated eosinophils, dupilumab reduced severe exacerbations by 50% when given at 200 mg and by 55% when given at 300 mg (P less than .001 vs. placebo).

In late-onset patients with elevated eosinophils, dupilumab reduced exacerbations by 65% and 73%, respectively (P less than .001 vs. placebo).

In patients with early-onset asthma and elevated FeNO, dupilumab reduced severe exacerbations by 56% when given at 200 mg and by 52% when given at 300 mg (P less than .001 vs. placebo). In late-onset patients with elevated FeNO, dupilumab reduced exacerbations by 79% and 71%, respectively (P less than .001 vs. placebo).

Dupilumab also improved prebronchodilator forced expiratory volume in 1 second (pre-BD FEV₁), compared with placebo, with similar results in early- and late-onset patients.

In early-onset patients, the P values were less than .001 for both doses of dupilumab at weeks 12 and 52.

In late-onset patients, the P values were less than .001 for the 300-mg dose at week 12 and the 200-mg dose at week 52, less than .01 for the 200-mg dose at week 12, and less than .05 for the 300-mg dose at week 52.

The effects of dupilumab on pre-BD FEV₁ were greatest in patients with elevated eosinophils or FeNO.

At week 12, the P-value was less than .001 for both doses of dupilumab in early-onset patients with elevated eosinophils or FeNO. The P-value was less than .01 for both doses in late-onset patients with elevated eosinophils. And the P-value was less than .001 for both doses in late-onset patients with elevated FeNO.

Read Also: Add on Dupilumab reduces asthma exacerbations

The bottom line of the study is -- Dupilumab is more effective in reducing severe asthma exacerbations in patients with late-onset asthma, but the drug’s effect on lung function appeared the same regardless of asthma onset.

More Information: "Dupilumab Reduces Severe Asthma Exacerbation Rate and Improves Lung Function Regardless of Age at Onset of Asthma: The Liberty Asthma Quest Study" published in the CHEST journal.

DOI: https://doi.org/10.1016/j.chest.2019.08.870

Journal Information: CHEST

Article Source : CHEST journal

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Dupilumab reduces exacerbation in both early and late onset asthma: CHEST

Similar News